BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came ...

CryptoAlerta — análise de criptomoedas e mercado em tempo real